Skip to main content
SpringerLink
Log in

FQAD and Neurotoxicity/Peripheral Neuropathy (PN)/Autonomic Neuropathy/Small Fibre Neuropathy

  • Chapter
  • First Online:
Fluoroquinolone-Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria

  • 320 Accesses

Abstract

The neurotoxic damage caused by fluoroquinolones is well documented. It includes not only peripheral nerve damage but also central, partly mononeuronal, involvement and autonomic neuropathies. Various approaches are being discussed for the pathogenesis, and some interesting therapeutic options have recently been added.

The high rate of positive tests for small fibre neuropathy should be emphasized.

The pathogenesis, diagnostics and therapeutic options are presented here.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 29.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother. 2001;35:1540–7. https://doi.org/10.1345/aph.1Z429.

    Article  CAS  PubMed  Google Scholar 

  2. FDA/CDER Drug Information Webinar. “Fluoroquinolone-Associated Disability” (FQAD). April 4, 2017.

    Google Scholar 

  3. Etminan M, et al. Oral fluoroquinolone use and risk of peripheral neuropathy. A pharmacoepidemiologic study. Neurology. 2014;83(14):1261–3. https://doi.org/10.1212/WNL.0000000000000846.

    Article  CAS  PubMed  Google Scholar 

  4. FDA Pharmacovigilance Review. Disabling peripheral neuropathy associated with systemic fluoroquinolone exposure. 2013.

    Google Scholar 

  5. FDA Drug Safety Communication. FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection Safety Announcement [8-15-2013]. 2013.

    Google Scholar 

  6. FDA’s Adverse Event Reporting System (FAERS). Review: “fluoroquinolone-associated disability” (FQAD). 2015.

    Google Scholar 

  7. Hedenmalm K, Spigset O. Peripheral sensory disturbances related to treatment with fluoroquinolones. J Antimicrob Chemother. 1996;37:831–7. https://doi.org/10.1093/jac/37.4.831.

    Article  CAS  PubMed  Google Scholar 

  8. Morales D, et al. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA Neurol. 2019;76(7):827–33. https://doi.org/10.1001/jamaneurol.2019.0887.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Golomb BA, et al. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep. 2015;2015. pii: bcr2015209821. https://doi.org/10.1136/bcr-2015-209821.

  10. Francis J. Permanent peripheral neuropathy, a case report on a rare but serious debilitating side-effect of fluoroquinolone administration. J Investig Med High Impact Case Rep. 2014;2(3):2324709614545225. https://doi.org/10.1177/2324709614545225.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Popescu C. Severe acute axonal neuropathy induced by ciprofloxacin: a case report. Case Rep Neurol. 2018;10:124–9. https://doi.org/10.1159/000489303.

    Article  PubMed  PubMed Central  Google Scholar 

  12. myquinstory October 25th, 2012 gastroparesis http://www.myquinstory.info.

  13. Samarakoon N, et al. Ciprofloxacin-induced toxic optic neuropathy. J Clin Exp Ophthalmol. 2007;35(1):102–4. https://doi.org/10.1111/j.1442-9071.2007.01427.x.

    Article  Google Scholar 

  14. Thomas RJ, Reagan DR. Association of a Tourette-like syndrome with ofloxacin. Ann Pharmacother. 1996;30(2):138–41. https://doi.org/10.1177/106002809603000205.

    Article  CAS  PubMed  Google Scholar 

  15. Ali AK, et al. Peripheral neuropathy and Guillain-Barré syndrome associated with exposure to systemic fluoroquinolones. Ann Epidemiol. 2014;24(4):279–85. https://doi.org/10.1016/j.annepidem.2013.12.009.

    Article  PubMed  Google Scholar 

  16. Liang VY, et al. Carpal tunnel syndrome after ciprofloxacin-induced tendinitis. J Clin Neuromuscul Dis. 2010;11(3):165–6. https://doi.org/10.1097/CND.0b013e3181d23a9c.

    Article  PubMed  Google Scholar 

  17. Kelentey B, et al. Modification of innervation pattern by fluoroquinolone treatment in the rat salivary glands. Anat Rec (Hoboken). 2010;293(2):271–9. https://doi.org/10.1002/ar.21037.

    Article  CAS  Google Scholar 

  18. Jumma OK, Dick J, et al. Ciprofloxacin induced acute small fibre neuropathy. Case report. Can J Neurol Sci. 2013;40(1):127–8. https://doi.org/10.1017/S031716710001742X.

    Article  PubMed  Google Scholar 

  19. de Schryver EL, et al. Small-fibre neuropathy can be detected in patients with chronic idiopathic axonal polyneuropathy. Eur J Neurol. 2011;18(7):1003–5. https://doi.org/10.1111/j.1468-1331.2010.03193.x.

    Article  PubMed  Google Scholar 

  20. Estofan LJF, et al. Quinolone-induced painful peripheral neuropathy: a case report and literature review. J Investig Med High Impact Case Rep. 2018;6:2324709617752736. https://doi.org/10.1177/2324709617752736.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Han T, et al. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012;167(4):465–71. https://doi.org/10.1530/EJE-12-0555.

    Article  CAS  PubMed  Google Scholar 

  22. Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721–31. https://doi.org/10.1517/14656566.2014.972935.

    Article  CAS  PubMed  Google Scholar 

  23. Mendoza-Núñez VM, et al. The effect of 600 mg alpha-lipoic acid supplementation on oxidative stress, inflammation, and RAGE in older adults with type 2 diabetes mellitus. Oxidative Med Cell Longev. 2019;2019:3276958. https://doi.org/10.1155/2019/3276958.

    Article  CAS  Google Scholar 

  24. Sima AA, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care. 2005;28(1):89–94. https://doi.org/10.2337/diacare.28.1.89.

    Article  CAS  PubMed  Google Scholar 

  25. Pace A, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74(9):762–6.

    Article  CAS  Google Scholar 

  26. Ghoreishi Z, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012;12:355. Can J Infect Dis. 2002; 13(1): 54–61.

    Article  CAS  Google Scholar 

  27. Negrão L, et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014;4(3):191–6. https://doi.org/10.2217/pmt.14.10.

    Article  PubMed  Google Scholar 

  28. Chowanadisai W, et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element- binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. 2010;285:142. https://doi.org/10.1074/jbc.M109.030130.

    Article  CAS  PubMed  Google Scholar 

  29. Mohar DS, Malik S. The sirtuin system: the holy grail of resveratrol? J Clin Exp Cardiolog. 2012;3(11):216. https://doi.org/10.4172/2155-9880.1000216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bowie WR, et al. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother. 1989;33(10):1778–82. https://doi.org/10.1128/AAC.33.10.1778.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Estofan LJF, et al. Quinolone-induced painful peripheral neuropathy: a case report and literature review. J Investig Med High Impact Case Rep. 2018;6:1–3. https://doi.org/10.1177/2324709617752736.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Konstanz, Baden-Württemberg, Germany

    Stefan Pieper

Authors
  1. Stefan Pieper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Pieper .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pieper, S. (2021). FQAD and Neurotoxicity/Peripheral Neuropathy (PN)/Autonomic Neuropathy/Small Fibre Neuropathy. In: Fluoroquinolone-Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria . Springer, Cham. https://doi.org/10.1007/978-3-030-74173-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74173-0_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74172-3

  • Online ISBN: 978-3-030-74173-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation